GGrantIndex
Sort

21,453 grants matching tuberculosis

Hospital and Household Studies of Respiratory Cryptosporidiosis and Transmission

$675,368
Jeffrey K Griffiths · Tufts University Boston · R01 · FY2016 · AI

Lung Ultrasound and Artificial Intelligence Technology for the Diagnosis of TB in LMICs

$675,306
Robert H Gilman · Johns Hopkins University · R01 · FY2024 · HL

A Rapid Phenotypic Drug Susceptibility Testing System for Tuberculosis

$675,156
Mireille Kamariza · University Of California Los Angeles · R01 · FY2024 · AI

Defining how the spectrum of latency affects reactivation of TB

$675,044
Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · HL

Oral Microbiome and Lung Cancer Risk

$674,957
Qiuyin Cai · Vanderbilt University Medical Center · R01 · FY2016 · CA

Dynamics of the cellular and molecular architecture of human pulmonary TB granulomas

$674,955
Robert L Modlin · University Of California Los Angeles · R01 · FY2022 · AI

Defining adaptive immune responses to Mtb-infection and TB disease among young children with and without HIV-exposure

$674,625
Christina Louise Lancioni · Oregon Health & Science University · R01 · FY2022 · AI

Mycobacterium tuberculosis antigen diversity

$674,536
Joel D. Ernst · New York University School Of Medicine · R01 · FY2011 · AI

Evaluating health and economic effects of targeted strategies in TB/HIV

$674,488
Theodore H Cohen · Yale University · R01 · FY2014 · AI

Expression signatures of TB-specific memory responses within the human lung

$674,453
Richard F Silver · Case Western Reserve University · R01 · FY2013 · HL

The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

$674,402
Shabaana A. Khader · Washington University · R01 · FY2021 · AI

The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

$674,402
Shabaana A. Khader · Washington University · R01 · FY2019 · AI

The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis

$674,402
Shabaana A. Khader · Washington University · R01 · FY2020 · AI

Inhibitors of latent M. tuberculosis

$674,231
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2011 · AI

Anti-TB sterilizing immunity in immune and HIV+ individuals

$674,207
Zheng W Chen · University Of Illinois At Chicago · R01 · FY2017 · HL

Host Response to TB and AIDS

$673,923
New York University School Of Medicine · R01 · FY2005 · HL

Diagnostics and Pharmacotherapy for Severe Forms of TB

$673,914
Scott K Heysell · University Of Virginia · U01 · FY2016 · AI

Trial of Vitamin D Supplementation to Prevent TB Infection in Schoolchildren

$673,745
Ganmaa Davaasambuu · Harvard School Of Public Health · R01 · FY2018 · HL

Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome

$673,634
Eric R Houpt · University Of Virginia · R01 · FY2023 · HL

Deep sequencing of pathogens to precisely define transmission networks using rare variants

$673,574
William Hanage · Harvard School Of Public Health · R01 · FY2017 · AI

Advancing innovative therapies against pandrug-resistant Gram-negative superbugs

$673,485
Qi Zhou · Purdue University · R01 · FY2019 · AI

Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.

$673,476
Jonathan E Golub · Johns Hopkins University · U01 · FY2021 · CA

Regulation Of Immunopathology In Bacterial And Parasitic Disease

$673,334
Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Mechanism Based Inhibition of M Tuberculosis Enzymes

$673,080
John S Blanchard · Albert Einstein College Of Medicine · R01 · FY2010 · AI

INNOVATIVE APPROACHES TO TUBERCULOSIS CONTROL

$673,072
Johns Hopkins University · U19 · FY2001 · AI